Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer–American... by Madhusmita Behera, PhD, Renjian Jiang, MS, Zhonglu Huang, MS, Becky Bunn, MS, Murry W. Wynes, PhD, Jeffrey Switchenko, PhD, Giorgio V. Scagliotti, MD, Chandra P. Belani, MD, Suresh S. Ramalingam, MD

Get full text

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report by Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD

Get full text

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience by A.J. Piper-Vallillo, MD, Julia K. Rotow, MD, Jacqueline V. Aredo, MD, Khvaramze Shaverdashvili, MD, PhD, Jia Luo, MD, Jennifer W. Carlisle, MD, Hatim Husain, MD, Alona Muzikansky, MA, Rebecca S. Heist, MD, Deepa Rangachari, MD, Suresh S. Ramalingam, MD, Heather A. Wakelee, MD, Helena A. Yu, MD, Lecia V. Sequist, MD, Joshua M. Bauml, MD, Joel W. Neal, MD, PhD, Zofia Piotrowska, MD, MHS

Get full text

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial by Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD

Get full text